| [1] |
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis[J]. J Carcinog, 2017, 23(6): 1388-1396.
|
| [2] |
Muz B, de la Puente P, Azab F, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy[J]. Hypoxia (Auckl), 2015, 3: 83-92.
|
| [3] |
Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance[J]. J Hepatol, 2014, 61(6): 1385-1396.
|
| [4] |
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-255.
|
| [5] |
Sangro B, Park JW, Cruz CMD, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459[J]. J Clin Oncol, 2016, 34(15_suppl): TPS4147-TPS4147.
|
| [6] |
Yau T, Kang YK, Kim TY, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients(pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040[J]. J Clin Oncol, 2019, 37(15_suppl): 4012.
|
| [7] |
Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2): 687-695.
|
| [8] |
Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions[J]. Nat Rev Clin Oncol, 2011, 8(5): 292-301.
|
| [9] |
Chen J, Zaidi S, Rao S, et al. Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-β pathway[J]. Gastroenterology, 2018, 154(1): 195-210.
|
| [10] |
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity, 2014, 41(1): 49-61.
|
| [11] |
Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing[J]. Cell, 2017, 169(7): 1342-1356.
|
| [12] |
Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients[J]. J Hepatol, 2009, 50(5): 980-989.
|
| [13] |
LaCasse CJ, Janikashvili N, Larmonier CB, et al. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-gamma-dependent mechanism[J]. J Immunol, 2011, 187(12): 6310-6317.
|
| [14] |
Lee HL, Jang JW, Lee SW, et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization[J]. Sci Rep, 2019, 9(1): 3260.
|
| [15] |
DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages[J]. Cancer Cell, 2009, 16(2): 91-102.
|
| [16] |
Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients[J]. Clin Immunol, 2008, 129(3): 428-437.
|
| [17] |
Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection[J]. Nature, 2006, 439(7077): 682-687.
|
| [18] |
Greten TF, Sangro B. Targets for immunotherapy of liver cancer[J]. J Hepatol, 2017, 68(1): 157-166.
|
| [19] |
Huppert LA, Gordan JD, Kelley RK. Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma[J]. Clin Liver Dis (Hoboken), 2020, 15(2): 53-58.
|
| [20] |
Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547): 373-377.
|
| [21] |
Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy[J]. Nat Immunol, 2002, 3(7): 611-618.
|
| [22] |
Lim CJ, Chew V. Impact of viral etiologies on the development of novel immunotherapy for hepatocellular carcinoma[J]. Semin Liver Dis, 2020, 40 (2): 131-142.
|
| [23] |
Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study[J]. J Natl Cancer Inst, 2016, 108(9): djw133.
|
| [24] |
Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31(13): 1631-1639.
|
| [25] |
Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study[J]. Hepatology, 2013, 57(5): 1826-1837.
|
| [26] |
Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells[J]. J ExpMed, 2000, 191(3): 423-434.
|
| [27] |
Deng L, Liang H, Xu M, et al. STING dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors[J]. Immunity, 2014, 41(5): 843-852.
|
| [28] |
Jacquelot N, Yamazaki T, Roberti MP, et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade[J]. Cell Res, 2019, 29(10): 846-861.
|
| [29] |
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19): 5458-5468.
|
| [30] |
Vermeer, DW, Spanos, WC, Vermeer, PD, et al. Radiation-induced loss of cell surface CD47 enhances immunemediated clearance of human papillomavirus-positive cancer[J]. Int J Cancer, 2013, 133: 120-129.
|
| [31] |
Yoshimoto Y, Oike T, Okonogi N, et al. Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation[J]. J Radiat Res, 2015, 56: 509-514.
|
| [32] |
shikawa H, Ma Z, Barber GN. STING regulates intracellular DNA mediated, type I interferon-dependent innate immunity[J]. Nature, 2009, 461: 788-792.
|
| [33] |
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19): 5458-5468.
|
| [34] |
Chiang CL, Chan ACY, Chiu KWH, et al. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy[J]. Front Oncol, 2019, 9: 1157.
|
| [35] |
Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells[J]. Clin Cancer Res, 2017, 23(6): 1388-1396.
|
| [36] |
Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation[J]. Front Oncol, 2018, 8: 612.
|
| [37] |
Bonta I, Isac JF, Meiri E, et al. Correlation between tumor mutation burden and response to immunotherapy[J]. J Clin Oncol, 2017, 35 (15_suppl): e14579.
|
| [38] |
Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy[J]. Oncol Targets Ther, 2018, 11: 6901-6909.
|
| [39] |
Asghar K, Farooq A, Zulfiqar B, et al. Indoleamine 2,3-dioxygenase: as a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma[J]. World J Gastroenterol, 2017, 23(13): 2286-2293.
|
| [40] |
Liu M, Li Z, Yao W, et al. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion[J]. Mol Med Rep, 2020, 21(1): 445-453.
|
| [41] |
Zheng Y, Liao N, Wu Y, et al. High expression of B7-H2 or B7-H3 is associated with poor prognosis in hepatocellular carcinoma[J]. Mol Med Rep, 2019, 19(5): 4315-4325.
|
| [42] |
Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors[J]. Int J Biol Sci, 2019, 15(12): 2548-2560.
|
| [43] |
Kaseb AO, Hassan M, Lacin S, et al. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma[J]. Oncotarget, 2016, 7(43): 69916-69926.
|
| [44] |
Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 t-cell therapy for advanced hepatocellular carcinoma: results of phase 1 trials[J]. Clin Cancer Res, 2020, 26(15): 3979-3989.
|
| [45] |
Forker LJ, Choudhury A, Kiltie AE. Biomarkers of tumour radiosensitivity and predicting benefit from radiotherapy[J]. Clin Oncol (R Coll Radiol), 2015, 27(10): 561-569.
|